Russian Journal of BiotherapyRussian Journal of BiotherapyРоссийский биотерапевтический журнал1726-97841726-9792Publishing House ABV Press112310.17650/1726-9784-2018-17-4-36-44REVIEWSОБЗОРЫ ЛИТЕРАТУРЫCancer vaccine adjuvantsАдъюванты в вакцинотерапии опухолейhttps://orcid.org/0000-0002-6688-8423BaryshnikovaM. A.БарышниковаМ. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

Мария Анатольевна Барышникова

ma_b@mail.ruhttps://orcid.org/0000-0002-8462-2178KosorukovV. S.КосоруковВ. С.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФБГУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России11122018174364410012019100120192018https://bioterapevt.abvpress.ru/jour/article/view/1123

Adjuvants are important components of cancer vaccines because they enhance immune responses to vaccination. However, adjuvants licensed for clinical use, e. g. aluminum salts, fail to stimulate an effective immune response. Research and development of new adjuvants with combined functions, including immune stimulation and antigen delivery, are a vital task for antitumor immunotherapy. Clinical trials of immune stimulating compounds, in particular Toll-like receptor (TLR) ligands, reveal their therapeutic potential as both antitumor agents and vaccine adjuvants.

Адъюванты – важные составляющие противоопухолевых вакцин, поскольку они усиливают иммунные ответы на вакцинацию. Однако разрешенные к применению адъюванты, например соли алюминия, недостаточно эффективно стимулируют иммунный ответ. Поиск и изучение свойств новых адъювантов, часто сочетающих в себе функции стимуляторов иммунитета с доставкой антигена к иммунным клеткам, на сегодняшний день являются актуальными задачами иммунотерапии. Клинические испытания иммуностимулирующих веществ, в частности лигандов Толл-лайк рецепторов (TLR), выявили их терапевтический потенциал не только как противоопухолевых агентов, но и как адъювантов к вакцинам.

cancer vaccine therapyneoantigensadjuvantsTLR ligandsвакцинотерапия опухолейнеоантигеныадъювантылиганды TLR1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–74. PMID: 21376230. DOI: 10.1016/j.cell.2011.02.013.Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–74. PMID: 21376230. DOI: 10.1016/j.cell.2011.02.013.2. McCarthy E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006;26:154–8. PMID: 16789469.McCarthy E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006;26:154–8. PMID: 16789469.3. Kawai T., Akira S. The role of patternrecognition receptors in innate immunity: update on Toll-like receptors. Nat Nat Immunol 2010;11(5):373–84. PMID: 20404851. DOI: 10.1038/ni.1863.Kawai T., Akira S. The role of patternrecognition receptors in innate immunity: update on Toll-like receptors. Nat Nat Immunol 2010;11(5):373–84. PMID: 20404851. DOI: 10.1038/ni.1863.4. Zhou J. Advances and prospects in cancer immunotherapy. New J Sci 2014; Article ID 745808. DOI: 10.1155/2014/745808.Zhou J. Advances and prospects in cancer immunotherapy. New J Sci 2014; Article ID 745808. DOI: 10.1155/2014/745808.5. Барышникова М.А., Кособокова Е.Н., Косоруков В.С. Неоантигены в иммунотерапии опухолей. Российский биотерапевтический журнал 2018;17(2):6–14. [Baryshnikova M.A., Kosobokova E.N., Kosorukov V.S. Neoantigens in tumor immunotherapy. Rossiysky Bioterapevtichesky Zhurnal = Russian Journal of Biotherapy 2018;17(2):6–14. (In Russ.)]. DOI: 10.17650/1726-9784-2018-17-2-6-14.Барышникова М.А., Кособокова Е.Н., Косоруков В.С. Неоантигены в иммунотерапии опухолей. Российский биотерапевтический журнал 2018;17(2):6–14. [Baryshnikova M.A., Kosobokova E.N., Kosorukov V.S. Neoantigens in tumor immunotherapy. Rossiysky Bioterapevtichesky Zhurnal = Russian Journal of Biotherapy 2018;17(2):6–14. (In Russ.)]. DOI: 10.17650/1726-9784-2018-17-2-6-14.6. Ott P.A., Hu Z., Keskin D.B. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017;547:217–21. PMID: 28678778. DOI: 10.1038/nature22991.Ott P.A., Hu Z., Keskin D.B. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017;547:217–21. PMID: 28678778. DOI: 10.1038/nature22991.7. Sahin U., Derhovanessian E., Miller M. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017;547:222–6. PMID: 28678784. DOI: 10.1038/nature23003.Sahin U., Derhovanessian E., Miller M. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017;547:222–6. PMID: 28678784. DOI: 10.1038/nature23003.8. Sonntag K., Hashimoto H., Eyrich M. et al. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report. J Transl Med 2018;16(1):23. PMID: 29409514. DOI: 10.1186/s12967-018-1382-1.Sonntag K., Hashimoto H., Eyrich M. et al. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report. J Transl Med 2018;16(1):23. PMID: 29409514. DOI: 10.1186/s12967-018-1382-1.9. Temizoz B., Kuroda E., Ishii K.J. Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol 2016;28(7):329–38. PMID: 27006304. DOI: 10.1093/intimm/dxw015.Temizoz B., Kuroda E., Ishii K.J. Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol 2016;28(7):329–38. PMID: 27006304. DOI: 10.1093/intimm/dxw015.10. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10(9):909–15. PMID: 15340416. DOI: 10.1038/nm1100.Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10(9):909–15. PMID: 15340416. DOI: 10.1038/nm1100.11. Барышников А.Ю. Принципы и практика вакцинотерапии рака. Бюллетень СО РАМН 2004;112(2):59–63. [Baryshnikov A.Yu. Principles and practice of cancer vaccinotherapy. Byulleten SO RAMN = Bulletin of the Siberian Division of Russian Medical Sciences Academy 2004;112(2):59–63. (In Russ.)].Барышников А.Ю. Принципы и практика вакцинотерапии рака. Бюллетень СО РАМН 2004;112(2):59–63. [Baryshnikov A.Yu. Principles and practice of cancer vaccinotherapy. Byulleten SO RAMN = Bulletin of the Siberian Division of Russian Medical Sciences Academy 2004;112(2):59–63. (In Russ.)].12. Banday A.H., Jeelani S., Hruby V.J. Cancer vaccine adjuvants – recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol 2015;37(1):1–11. PMID: 25318595. DOI: 10.3109/08923973.2014.971963.Banday A.H., Jeelani S., Hruby V.J. Cancer vaccine adjuvants – recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol 2015;37(1):1–11. PMID: 25318595. DOI: 10.3109/08923973.2014.971963.13. Brewer J.M. (How) do aluminium adjuvants work? Immunol Lett 2006;102(1):10–5. PMID: 16188325. DOI: 10.1016/j.imlet.2005.08.002.Brewer J.M. (How) do aluminium adjuvants work? Immunol Lett 2006;102(1):10–5. PMID: 16188325. DOI: 10.1016/j.imlet.2005.08.002.14. Alfonso S., Valdes-Zayas A., Santiesteban E.R. et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 2014;20(14):3660–71. PMID: 24788102. DOI: 10.1158/1078-0432.CCR-13-1674.Alfonso S., Valdes-Zayas A., Santiesteban E.R. et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 2014;20(14):3660–71. PMID: 24788102. DOI: 10.1158/1078-0432.CCR-13-1674.15. Hutchison S., Benson R.A., Gibson V.B. et al. Antigen depot is not required for alum adjuvanticity. Fed Am Soc Exp Biol 2012;26:1272. PMID: 22106367. DOI: 10.1096/fj.11-184556.Hutchison S., Benson R.A., Gibson V.B. et al. Antigen depot is not required for alum adjuvanticity. Fed Am Soc Exp Biol 2012;26:1272. PMID: 22106367. DOI: 10.1096/fj.11-184556.16. Marichal T., Ohata K., Bedoret D. et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011;17:996. PMID: 21765404. DOI: 10.1038/nm.2403.Marichal T., Ohata K., Bedoret D. et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011;17:996. PMID: 21765404. DOI: 10.1038/nm.2403.17. Schwendener R.A. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines 2014;2(6):159–82. PMID: 25364509. DOI: 10.1177/2051013614541440.Schwendener R.A. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines 2014;2(6):159–82. PMID: 25364509. DOI: 10.1177/2051013614541440.18. Allison A., Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974;252(5480):252. PMID: 4424229.Allison A., Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974;252(5480):252. PMID: 4424229.19. Allison A., Gregoriadis G. Liposomes as immunological adjuvants. Recent Results Cancer Res 1976;(56):58–64. PMID: 188085.Allison A., Gregoriadis G. Liposomes as immunological adjuvants. Recent Results Cancer Res 1976;(56):58–64. PMID: 188085.20. Райков А.О., Хашем А., Барышникова М.А. Липосомы для направленной доставки противоопухолевых препаратов. Российский биотерапевтический журнал 2016;15(2):90–6. [Raikov A.O., Hashem A., Baryshnikova M.A. Liposomes as target delivery of antitumor drugs. Rossiysky Bioterapevtichesky Zhurnal = Russian Journal of Biotherapy 2016;15(2):90–6. (In Russ.)]. DOI: 10.17650/1726-9784-2016-15-2-90-96.Райков А.О., Хашем А., Барышникова М.А. Липосомы для направленной доставки противоопухолевых препаратов. Российский биотерапевтический журнал 2016;15(2):90–6. [Raikov A.O., Hashem A., Baryshnikova M.A. Liposomes as target delivery of antitumor drugs. Rossiysky Bioterapevtichesky Zhurnal = Russian Journal of Biotherapy 2016;15(2):90–6. (In Russ.)]. DOI: 10.17650/1726-9784-2016-15-2-90-96.21. Барышникова М.А., Барышников А.Ю. Иммунолипосомы и мишени их действия. Российский химический журнал 2012;LVI(3–4):60–6. [Baryshnikova M.A., Baryshnikov A.Yu. Immunoliposomes and their targets. Rossiyskiy Khimicheskiy Zhurnal = Russian Journal of General Chemistry 2012; LVI(3–4):60–6. (In Russ.)].Барышникова М.А., Барышников А.Ю. Иммунолипосомы и мишени их действия. Российский химический журнал 2012;LVI(3–4):60–6. [Baryshnikova M.A., Baryshnikov A.Yu. Immunoliposomes and their targets. Rossiyskiy Khimicheskiy Zhurnal = Russian Journal of General Chemistry 2012; LVI(3–4):60–6. (In Russ.)].22. Афанасьева Д.А., Барышникова М.А., Щербаков А.И. и др. Разработка модели противоопухолевой липосомальной вакцины. Иммунология 2014:35(6):317–21. [Afanasieva D.A., Baryshnikova M.A., Scherbakov A.I. et al. The development of anticancer liposomal vaccine model. Immunologiya = Immunology 2014;35(6):317–21. (In Russ.)].Афанасьева Д.А., Барышникова М.А., Щербаков А.И. и др. Разработка модели противоопухолевой липосомальной вакцины. Иммунология 2014:35(6):317–21. [Afanasieva D.A., Baryshnikova M.A., Scherbakov A.I. et al. The development of anticancer liposomal vaccine model. Immunologiya = Immunology 2014;35(6):317–21. (In Russ.)].23. Alving C.R., Beck Z., Matyas G.R., Rao M. Liposomal adjuvants for human vaccines. Expert Opin Drug Deliv 2016;13(6):807–16. PMID: 26866300. DOI: 10.1517/17425247.2016.1151871.Alving C.R., Beck Z., Matyas G.R., Rao M. Liposomal adjuvants for human vaccines. Expert Opin Drug Deliv 2016;13(6):807–16. PMID: 26866300. DOI: 10.1517/17425247.2016.1151871.24. Brignole C., Marimpietri D., Di Paolo D. et al. Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma. Cancer Res 2010;70(23):9816–26. PMID: 20935225. DOI: 10.1158/0008-5472.CAN-10-1251.Brignole C., Marimpietri D., Di Paolo D. et al. Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma. Cancer Res 2010;70(23):9816–26. PMID: 20935225. DOI: 10.1158/0008-5472.CAN-10-1251.25. Zhong Z., Wei X., Qi B. et al. A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice. Int J Pharm 2010;399(1–2):156–62. PMID: 20692327. DOI: 10.1016/j.ijpharm.2010.07.053.Zhong Z., Wei X., Qi B. et al. A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice. Int J Pharm 2010;399(1–2):156–62. PMID: 20692327. DOI: 10.1016/j.ijpharm.2010.07.053.26. Nakamura T., Yamazaki D., Yamauchi J., Harashima H. The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration. J Control Release 2013;171(2):216–24. PMID: 23860186. DOI: 10.1016/j.jconrel.2013.07.004.Nakamura T., Yamazaki D., Yamauchi J., Harashima H. The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration. J Control Release 2013;171(2):216–24. PMID: 23860186. DOI: 10.1016/j.jconrel.2013.07.004.27. Neelapu S.S., Baskar S., Gause B.L. et al. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res 2004;10(24):8309–17. PMID: 15623607. DOI: 10.1158/1078-0432.CCR-04-1071.Neelapu S.S., Baskar S., Gause B.L. et al. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res 2004;10(24):8309–17. PMID: 15623607. DOI: 10.1158/1078-0432.CCR-04-1071.28. Saga K., Kaneda Y. Virosome presents multimodel cancer therapy without viral replication. Biomed Res Int 2013;2013:764706. PMID: 24369016. DOI: 10.1155/2013/764706.Saga K., Kaneda Y. Virosome presents multimodel cancer therapy without viral replication. Biomed Res Int 2013;2013:764706. PMID: 24369016. DOI: 10.1155/2013/764706.29. Trovato M., De Berardinis P. Novel antigen delivery systems. World J Virol 2015;4(3):156–68. PMID: 26279977. DOI: 10.5501/wjv.v4.i3.156.Trovato M., De Berardinis P. Novel antigen delivery systems. World J Virol 2015;4(3):156–68. PMID: 26279977. DOI: 10.5501/wjv.v4.i3.156.30. Almeida J.D., Edwards D.C., Brand C.M., Heath T.D. Formation of virosomes from influenza subunits and liposomes. Lancet 1975;2:899–901. PMID: 53375. DOI:10.1016/s0140-6736(75)92130–3.Almeida J.D., Edwards D.C., Brand C.M., Heath T.D. Formation of virosomes from influenza subunits and liposomes. Lancet 1975;2:899–901. PMID: 53375. DOI:10.1016/s0140-6736(75)92130–3.31. Jamali A., Holtrop M., de Haan A. et al. Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination. Immunol Lett 2012;148(1):77–82. PMID: 22981929. DOI: 10.1016/j.imlet.2012.08.006.Jamali A., Holtrop M., de Haan A. et al. Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination. Immunol Lett 2012;148(1):77–82. PMID: 22981929. DOI: 10.1016/j.imlet.2012.08.006.32. Yang X., Lian K., Meng T. et al. Immune adjuvant targeting micelles allow efficient dendritic cell migration to lymph nodes for enhanced cellular immunity. ACS Appl Mater Interfaces 2018;10(39): 33532–44. PMID: 30192498. DOI: 10.1021/acsami. 8b10081.Yang X., Lian K., Meng T. et al. Immune adjuvant targeting micelles allow efficient dendritic cell migration to lymph nodes for enhanced cellular immunity. ACS Appl Mater Interfaces 2018;10(39): 33532–44. PMID: 30192498. DOI: 10.1021/acsami. 8b10081.33. Qiu F., Becker K.W., Knight F.C. et al. Poly(propylacrylic acid) – peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines. Biomaterials 2018;182:82–91. PMID: 30107272. DOI: 10.1016/j.biomaterials.2018.07.052.Qiu F., Becker K.W., Knight F.C. et al. Poly(propylacrylic acid) – peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines. Biomaterials 2018;182:82–91. PMID: 30107272. DOI: 10.1016/j.biomaterials.2018.07.052.34. Wilson N.S., Duewell P., Yang B. et al. Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant. J Immunol 2014;192(7):3259–68. PMID: 24610009. DOI: 10.4049/jimmunol.1302011.Wilson N.S., Duewell P., Yang B. et al. Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant. J Immunol 2014;192(7):3259–68. PMID: 24610009. DOI: 10.4049/jimmunol.1302011.35. Davis I.D., Chen W., Jackson H. et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004;101(29): 10697–702. PMID: 15252201. DOI: 10.1073/pnas. 0403572101.Davis I.D., Chen W., Jackson H. et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004;101(29): 10697–702. PMID: 15252201. DOI: 10.1073/pnas. 0403572101.36. Davis I.D., Quirk J., Morris L. et al. A pilot study of peripheral blood BDCA-1(CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant. Immunotherapy 2017;9(3):249–59. PMID: 28183192. DOI: 10.2217/imt-2016-0132.Davis I.D., Quirk J., Morris L. et al. A pilot study of peripheral blood BDCA-1(CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant. Immunotherapy 2017;9(3):249–59. PMID: 28183192. DOI: 10.2217/imt-2016-0132.37. Silva A., Mount A., Krstevska K. et al. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo. J Immunol 2015;194(5): 2199–207. PMID: 25646304. DOI: 10.4049/jimmunol. 1402228.Silva A., Mount A., Krstevska K. et al. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo. J Immunol 2015;194(5): 2199–207. PMID: 25646304. DOI: 10.4049/jimmunol. 1402228.38. Goldberg J.L., Sondel P.M. Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Semin Oncol 2015;42(4):562–72. PMID: 26320061. DOI: 10.1053/j.seminoncol.2015.05.012.Goldberg J.L., Sondel P.M. Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Semin Oncol 2015;42(4):562–72. PMID: 26320061. DOI: 10.1053/j.seminoncol.2015.05.012.39. Gosu V., Basith Sh., Kwon O.P., Choi S. Therapeutic applications of nucleic acids and their analogues in toll-like receptor signaling. Molecules 2012;17:13503–29. PMID: 23151919. DOI: 10.3390/molecules171113503.Gosu V., Basith Sh., Kwon O.P., Choi S. Therapeutic applications of nucleic acids and their analogues in toll-like receptor signaling. Molecules 2012;17:13503–29. PMID: 23151919. DOI: 10.3390/molecules171113503.40. Schwarz T.F. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine. Cervarix Adv Ther 2009;26(11):983–98. PMID: 20024678. DOI: 10.1007/s12325-009-0079-5.Schwarz T.F. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine. Cervarix Adv Ther 2009;26(11):983–98. PMID: 20024678. DOI: 10.1007/s12325-009-0079-5.41. Ferreira Costa A.P., Gonçalves A.K., Machado P.R. L. et al. Immune response to human papillomavirus one year after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: HPV-specific IgG and IgA antibodies in the circulation and the cervix. Asian Pac J Cancer Prev 2018;19(8):2313–7. PMID: 30141308. DOI: 10.22034/APJCP.2018.19.8.2313.Ferreira Costa A.P., Gonçalves A.K., Machado P.R. L. et al. Immune response to human papillomavirus one year after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: HPV-specific IgG and IgA antibodies in the circulation and the cervix. Asian Pac J Cancer Prev 2018;19(8):2313–7. PMID: 30141308. DOI: 10.22034/APJCP.2018.19.8.2313.42. Huen A.O., Rook A.H. Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma. Curr Opin Oncol 2014;26(2):237–44. PMID: 24441505. DOI: 10.1097/CCO.0000000000000048.Huen A.O., Rook A.H. Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma. Curr Opin Oncol 2014;26(2):237–44. PMID: 24441505. DOI: 10.1097/CCO.0000000000000048.43. Junt T., Barchet W. Translating nucleic acid-sensing pathways into therapies. Nat Rev Immunol 2015;15(9):529–44. PMID: 26292638. DOI: 10.1038/nri3875.Junt T., Barchet W. Translating nucleic acid-sensing pathways into therapies. Nat Rev Immunol 2015;15(9):529–44. PMID: 26292638. DOI: 10.1038/nri3875.44. Ren S., Wang Q., Zhang Y. et al. Imiquimod enhances the potency of an exogenous BM–DC based vaccine against mouse melanoma. Int Immunopharmacol 2018;64:69–77. PMID: 30149266. DOI: 10.1016/j.intimp.2018.08.026.Ren S., Wang Q., Zhang Y. et al. Imiquimod enhances the potency of an exogenous BM–DC based vaccine against mouse melanoma. Int Immunopharmacol 2018;64:69–77. PMID: 30149266. DOI: 10.1016/j.intimp.2018.08.026.45. Paßlick D., Piradashvili K., Bamberger D. et al. Delivering all in one: Antigen-nanocapsule loaded with dual adjuvant yields superadditive effects by DC-directed T cell stimulation. J Control Release 2018;289:23–34. PMID: 30219277. DOI: 10.1016/j.jconrel.2018.09.008.Paßlick D., Piradashvili K., Bamberger D. et al. Delivering all in one: Antigen-nanocapsule loaded with dual adjuvant yields superadditive effects by DC-directed T cell stimulation. J Control Release 2018;289:23–34. PMID: 30219277. DOI: 10.1016/j.jconrel.2018.09.008.46. Ignatz-Hoover J.J., Wang H., Moreton S.A. et al. The role of TLR8 signaling in Acute Myeloid Leukemia Differentiation. Leukemia 2015;29(4):918–26. PMID: 25283842. DOI: 10.1038/leu.2014.293.Ignatz-Hoover J.J., Wang H., Moreton S.A. et al. The role of TLR8 signaling in Acute Myeloid Leukemia Differentiation. Leukemia 2015;29(4):918–26. PMID: 25283842. DOI: 10.1038/leu.2014.293.47. Chen K., Wu Z., Zang M. et al. Immunization with glypican-3 nanovaccine containing TLR7 agonist prevents the development of carcinogeninduced precancerous hepatic lesions to cancer in a murine model. Am J Transl Res 2018;10(6):1736–49. PMID: 30018715.Chen K., Wu Z., Zang M. et al. Immunization with glypican-3 nanovaccine containing TLR7 agonist prevents the development of carcinogeninduced precancerous hepatic lesions to cancer in a murine model. Am J Transl Res 2018;10(6):1736–49. PMID: 30018715.48. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5(6):471–84. PMID: 16763660. DOI: 10.1038/nrd2059.Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5(6):471–84. PMID: 16763660. DOI: 10.1038/nrd2059.49. Temizoz B., Kuroda E., Ishii K.J. Combination and inducible adjuvants targeting nucleic acid sensors. Curr Opin Pharmacol 2018;41:104–13. PMID: 29870915. DOI: 10.1016/j.coph.2018.05.003.Temizoz B., Kuroda E., Ishii K.J. Combination and inducible adjuvants targeting nucleic acid sensors. Curr Opin Pharmacol 2018;41:104–13. PMID: 29870915. DOI: 10.1016/j.coph.2018.05.003.50. Temizoz B., Kuroda E., Ohata K. et al. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. Eur J Immunol 2015;45(4):1159–69. PMID: 25529558. DOI: 10.1002/eji.201445132.Temizoz B., Kuroda E., Ohata K. et al. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. Eur J Immunol 2015;45(4):1159–69. PMID: 25529558. DOI: 10.1002/eji.201445132.51. Ammi R., De Waele J., Willemen Y. et al. Poly(I: C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol Ther 2015;146:120–31. PMID: 25281915. DOI: 10.1016/j.pharmthera.2014.09.010.Ammi R., De Waele J., Willemen Y. et al. Poly(I: C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol Ther 2015;146:120–31. PMID: 25281915. DOI: 10.1016/j.pharmthera.2014.09.010.52. Cheever M.A. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008;222:357–68. PMID: 18364014. DOI: 10.1111/j.1600-065X.2008.00604.x.Cheever M.A. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008;222:357–68. PMID: 18364014. DOI: 10.1111/j.1600-065X.2008.00604.x.53. Longhi M.P., Trumpfheller C., Idoyaga J. et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009;206(7):1589–602. PMID: 19564349. DOI: 10.1084/jem.20090247.Longhi M.P., Trumpfheller C., Idoyaga J. et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009;206(7):1589–602. PMID: 19564349. DOI: 10.1084/jem.20090247.54. Cheng Y.S., Xu F. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther 2010;10(12):1219–23. PMID: 20930504.Cheng Y.S., Xu F. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther 2010;10(12):1219–23. PMID: 20930504.55. Klein J.C., Wild C.A., Lang S., Brandau S. Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands. Cancer Immunol Immunother 2016;65(6):689–700. PMID: 27034235. DOI: 10.1007/s00262-016-1828-3.Klein J.C., Wild C.A., Lang S., Brandau S. Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands. Cancer Immunol Immunother 2016;65(6):689–700. PMID: 27034235. DOI: 10.1007/s00262-016-1828-3.56. Bayyurt B., Tincer G., Almacioglu K. et al. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development. J Control Release 2017;247:134–44. PMID: 28069554. DOI: 10.1016/j. jconrel. 2017.01.004.Bayyurt B., Tincer G., Almacioglu K. et al. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development. J Control Release 2017;247:134–44. PMID: 28069554. DOI: 10.1016/j. jconrel. 2017.01.004.57. Duong H.T. T., Yin Y., Thambi T. et al. Smart vaccine delivery based on microneedle arrays decorated with ultrapH-responsive copolymers for cancer immunotherapy. Biomaterials 2018;185:13–24. PMID: 30216806. DOI: 10.1016/j.biomaterials.2018.09.008.Duong H.T. T., Yin Y., Thambi T. et al. Smart vaccine delivery based on microneedle arrays decorated with ultrapH-responsive copolymers for cancer immunotherapy. Biomaterials 2018;185:13–24. PMID: 30216806. DOI: 10.1016/j.biomaterials.2018.09.008.58. Levy H.B., Baer G., Baron S. et al. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis 1975;132(4):434–9. PMID: 810520.Levy H.B., Baer G., Baron S. et al. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis 1975;132(4):434–9. PMID: 810520.59. Salazar A.M., Levy H.B. et al. Longterm treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 1996;38(6):1096–103; discussion 1103–4. PMID: 8727138.Salazar A.M., Levy H.B. et al. Longterm treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 1996;38(6):1096–103; discussion 1103–4. PMID: 8727138.60. Hafner A.M., Corthésy B., Merkle H.P. Particulate formulations for the delivery of poly (I: C) as vaccine adjuvant. Adv Drug Deliv Rev 2013;65(10):1386–99. PMID: 23751781. DOI: 10.1016/j.addr.2013.05.013.Hafner A.M., Corthésy B., Merkle H.P. Particulate formulations for the delivery of poly (I: C) as vaccine adjuvant. Adv Drug Deliv Rev 2013;65(10):1386–99. PMID: 23751781. DOI: 10.1016/j.addr.2013.05.013.61. Jasani B., Navabi H., Adams M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009;27:3401. PMID: 19200817. DOI: 10.1016/j.vaccine.2009.01.071.Jasani B., Navabi H., Adams M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009;27:3401. PMID: 19200817. DOI: 10.1016/j.vaccine.2009.01.071.62. Okada H., Kalinski P., Ueda R. et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha} -type 1 polarized dendritic cells and polyinosinic – polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011;29(3):330–6. PMID: 21149657. DOI: 10.1200/JCO.2010.30.7744.Okada H., Kalinski P., Ueda R. et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha} -type 1 polarized dendritic cells and polyinosinic – polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011;29(3):330–6. PMID: 21149657. DOI: 10.1200/JCO.2010.30.7744.63. Prins R.M., Soto H., Konkankit V. et al. Gene expression profile correlateswith T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011;17(6):1603–15. PMID: 21135147. DOI: 10.1158/1078-0432.CCR-10-2563.Prins R.M., Soto H., Konkankit V. et al. Gene expression profile correlateswith T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011;17(6):1603–15. PMID: 21135147. DOI: 10.1158/1078-0432.CCR-10-2563.64. Morse M.A., Chapman R., Powderly J. et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res 2011;17(14):4844–53. PMID: 2163285. DOI: 10.1158/1078-0432.CCR-11-0891.Morse M.A., Chapman R., Powderly J. et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res 2011;17(14):4844–53. PMID: 2163285. DOI: 10.1158/1078-0432.CCR-11-0891.65. Dhodapkar M.V., Sznol M., Zhao B. et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014;6(232):232–51. PMID: 24739759. DOI: 10.1126/scitranslmed.3008068.Dhodapkar M.V., Sznol M., Zhao B. et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014;6(232):232–51. PMID: 24739759. DOI: 10.1126/scitranslmed.3008068.66. Sabbatini P., Tsuji T., Ferran L. et al. Phase I trial of overlapping long peptides from a tumor self-antigen and polyICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 2012;18(23):6497–508. PMID: 23032745. DOI: 10.1158/1078-0432.CCR-12-2189.Sabbatini P., Tsuji T., Ferran L. et al. Phase I trial of overlapping long peptides from a tumor self-antigen and polyICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 2012;18(23):6497–508. PMID: 23032745. DOI: 10.1158/1078-0432.CCR-12-2189.